| Assessment Status | Rapid Review complete |
| HTA ID | 21026 |
| Drug | Cabotegravir/Rilpivirine |
| Brand | Vocabria®/Rekambys® |
| Indication | HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. |
| Assessment Process | |
| Rapid review commissioned | 15/06/2021 |
| Rapid review completed | 21/07/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that cabotegravir in combination with rilpivirine not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations February 2022.
